The neurologic pain signature responds to nonsteroidal anti-inflammatory treatment vs placebo in knee osteoarthritis.

ABSTRACT:

Introduction

Many drug trials for chronic pain fail because of high placebo response rates in primary endpoints. Neurophysiological measures can help identify pain-linked pathophysiology and treatment mechanisms. They can also help guide early stop/go decisions, particularly if they respond to verum treatment but not placebo. The neurologic pain signature (NPS), an fMRI-based measure that tracks evoked pain in 40 published samples and is insensitive to placebo in healthy adults, provides a potentially useful neurophysiological measure linked to nociceptive pain.

Objectives

This study aims to validate the NPS in knee osteoarthritis (OA) patients and test the effects of naproxen on this signature.

Methods

In 2 studies (50 patients, 64.6 years, 75% females), we (1) test

SUBMITTER: Lopez-Sola M 

PROVIDER: S-EPMC8853614 | biostudies-literature | 2022 Mar-Apr

REPOSITORIES: biostudies-literature